Literature DB >> 29250900

Complications of botulinum toxin injection for masseter hypertrophy: Incidence rate from 2036 treatments and summary of causes and preventions.

Hsien-Li Peter Peng1, Jui-Hui Peng2.   

Abstract

BACKGROUND: Masseter hypertrophy is a common, prominent feature in many Asian patients, and correction procedures are often requested for esthetic reasons. Toxin masseter injections have a high efficacy and safety profile, but the risks of a variety of side effects or complications remain.
OBJECTIVES: The categorization of various complications was based on etiology, with a presentation of the author's own incidence rates for consideration and comparison.
METHODS: Six hundred and eighty patients received a total of 2036 sessions of toxin injection for masseter hypertrophy from 2011 to 2016, and complications or complaints were recorded through follow-up on a by-treatment basis. Complications were grouped together based on etiology and discussed.
RESULTS: Of 2036 sessions, temporary mastication force decrease was reported after 611 (30%), bruising after 51 (2.5%), headaches after 12 (0.58%), smile limitation after 3 (0.15%), paradoxical bulging after 10 (0.49%), sunken cheeks (subzygomatic volume loss) after 9 (0.44%), and sagging after 4 (0.20%).
CONCLUSIONS: Masseter injections remain very safe. To further decrease the incidence rate, injections should only be inside the recommended safety zone, a quadrilateral within the muscle that avoids most important local structures. Keeping injections inside the safe zone, and ideally in 3-4 different locations at least 1 cm from any border, is crucial for the prevention of complications.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  botulinum toxin injection; complications; incidence rate; masseter hypertrophy; masseter prominence; prevention

Mesh:

Substances:

Year:  2017        PMID: 29250900     DOI: 10.1111/jocd.12473

Source DB:  PubMed          Journal:  J Cosmet Dermatol        ISSN: 1473-2130            Impact factor:   2.696


  8 in total

1.  Intramuscular Neural Distribution of the Serratus Anterior Muscle: Regarding Botulinum Neurotoxin Injection for Treating Myofascial Pain Syndrome.

Authors:  Kyu-Ho Yi; Ji-Hyun Lee; Hee-Jin Kim
Journal:  Toxins (Basel)       Date:  2022-04-11       Impact factor: 5.075

2.  Intraductal Salivary Gland Infusion With Botulinum Toxin.

Authors:  Adam T Schwalje; Henry T Hoffman
Journal:  Laryngoscope Investig Otolaryngol       Date:  2019-09-03

Review 3.  The whole truth about botulinum toxin - a review.

Authors:  Henryk Witmanowski; Katarzyna Błochowiak
Journal:  Postepy Dermatol Alergol       Date:  2019-02-05       Impact factor: 1.837

4.  Prevention and correction of paradoxical masseteric bulging following botulinum toxin injection for masseter hypertrophy.

Authors:  Shauna M Rice; Janelle S Nassim; Erin M Hersey; Arianne Shadi Kourosh
Journal:  Int J Womens Dermatol       Date:  2021-03-06

5.  Ultrasound Imaging of the Facial Muscles and Relevance with Botulinum Toxin Injections: A Pictorial Essay and Narrative Review.

Authors:  Wei-Ting Wu; Ke-Vin Chang; Hsiang-Chi Chang; Lan-Rong Chen; Chen-Hsiang Kuan; Jung-Ting Kao; Ling-Ying Wei; Yunn-Jy Chen; Der-Sheng Han; Levent Özçakar
Journal:  Toxins (Basel)       Date:  2022-01-27       Impact factor: 4.546

Review 6.  Botulinum Toxin Therapy for Oromandibular Dystonia and Other Movement Disorders in the Stomatognathic System.

Authors:  Kazuya Yoshida
Journal:  Toxins (Basel)       Date:  2022-04-14       Impact factor: 5.075

7.  Topographic anatomical localization of the motor nerve entry points (MEPs) of the masseter muscle.

Authors:  Istemihan Coban; Kaan Yucel; Yelda Pinar
Journal:  Surg Radiol Anat       Date:  2021-06-09       Impact factor: 1.246

8.  Comparison between Conventional Blind Injections and Ultrasound-Guided Injections of Botulinum Toxin Type A into the Masseter: A Clinical Trial.

Authors:  Hyungkyu Bae; Jisoo Kim; Kyle K Seo; Kyung-Seok Hu; Seong-Taek Kim; Hee-Jin Kim
Journal:  Toxins (Basel)       Date:  2020-09-11       Impact factor: 4.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.